I will be present at the High content Analysis and 3D Screening Conference in Boston from Monday (November 7)  to Wednesday (November 9).

“Now in its fifteenth year, Cambridge Healthtech Institute’s High-Content Analysis & 3D Screening Conference will deliver the most recent developments in high-content and phenotypic screening. Leading pharma and academic researchers will focus on advancements in HCA technologies and applications, including screening of 3D and physiologically-relevant cellular models, data analysis techniques, and case studies and strategies for successful drug discovery. The expanded 3-day coverage on 3D cellular models and 3D screening will present the latest in spheroid, organoid and organotypic cell culture, and organ-on-a-chip technologies for drug screening, toxicity testing, and disease modeling.”

In this conference, I will present a poster on our collaborative work with Dr Karim Si-Tayeb, researcher from Institut du Thorax (CHOPIN project) on differentiation of iPS in hepatocytes in 3D culture for metabolic diseases screening.

If you want to know more on this project, don’t hesitate to come and discuss with me or contact us.

Méryl Roudaut* will present a poster on the work of Institut du Thorax (Nantes, France) during the meeting “advances in cell engineering, imaging and screening conference”. This conference will be held on 17-18 november 2016, in Louvain (Belgium). It will focus on novel technologies through presentations in several sessions:

  • New imaging and microscopy tools
  • Super-resolution Imaging
  • IPS and cell reprogramming
  • 3D cell culture and organoids
  • Cell manipulation
  • In vivo cell-based assays
  • Cytometry
  • High Content Screening.

If you want more informations about the CHOPIN program and the work presented on the poster, don’t hesitate to discuss with Méryl* during this event!

*Méryl is our PhD student working in collaboration with Pr Bertrand Cariou and Dr Karim Si-Tayeb within the CHOPIN RHU program.

Cosm'ing

HCS Pharma is pleased to participate to the Cosm’ing meeting about technological developments in the cosmetic industry. Come and discover our services in Saint-Malo from the 29th June to the first of July 2016. We will present our expertise in cellomic (an imaging approach of cells), giving early results on the effectiveness and the toxicity of active ingredients.

Bannière cosm'ing

On the program: seminar, roundtables and posters on innovation upon different subjects:

  • Vegetal and marine cell cultures,
  • Enzymatic and fermentation processes,
  • Cutaneous Microbiology,
  • The contribution of “omics” in cosmetics

In this last session, Julian Bursztyka from HCS Pharma will give a talk on: «Cellomic»: Automation, cellular imaging and High Content analysis as an integrated tool to serve innovation in dermo-cosmetic”. He will also present a poster on a genotoxicity assay in High Content Screening developed in collaboration with the “toxicology in vitro team” of Galderma R&D.

Cosm'ing

As shown by AstraZeneca in nature reviews, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs . To avoid this attrition, the potential neurotoxicity  of any drug going through the blood brain barrier (BBB) needs to be checked and if possible at the early stage of  the research process for new chemical entites (NCE). This assay can be performed by cell imaging in HCA/HCS.

View and download on Slideshare (low quality) :
http://fr.slideshare.net/hcspharma/neurotoxicity-assay-using-high-content-screening-technology

Ask for high quality link  by putting your email below

This new microscopy technology is a promising tool for in vivo 3D imaging of fast dynamic processes in cells and embryos. Lattice light-sheet microscopy allows fast 3D superresolution, with lower photobleaching and phototoxicity.

Here is the Editor’s summary about this article published in Science 2 weeks ago (Chen et al.) :

From single molecules to embryos in living color

Animation defines life, and the three-dimensional (3D) imaging of dynamic biological processes occurring within living specimens is essential to understand life. However, in vivo imaging, especially in 3D, involves inevitable tradeoffs of resolution, speed, and phototoxicity. Chen et al. describe a microscope that can address these concerns. They used a class of nondiffracting beams, known as 2D optical lattices, which spread the excitation energy across the entire field of view while simultaneously eliminating out-of-focus excitation. Lattice light sheets increase the speed of image acquisition and reduce phototoxicity, which expands the range of biological problems that can be investigated. The authors illustrate the power of their approach using 20 distinct biological systems ranging from single-molecule binding kinetics to cell migration and division, immunology, and embryonic development.

More and more articles show the advantages of culture compared to 2D in field. This article describe how to do high throughput using 3D culture by rapid size profiling analysis over time on tumor spheroids.

“Tumor size is the most frequently used in vivo endpoint when assessing antitumor efficacy in animal xenograft models, whereas proliferation is the more typically evaluated growth endpoint in vitro using two-dimensional (2D) monolayer cultures. Such 2D in vitro assays frequently fail to correlate with in vivo observations, owing to the inability of 2D cultures to recapitulate the native tumor microenvironment described above. Three-dimensional (3D) tumor microtissues, or multicellular tumor spheroids, are considered a more representative, organotypic model for assessment of tumor growth. They contain layers of cells that exhibit more in vivo-like size- and gradient-dependent proliferation and viability profiles.”

To know more about this article, follow this link: http://www.genengnews.com/gen-articles/phenotypic-drug-discovery-in-3d/5303/

The Vision Summit interviewed Dr Urban Liebel, co-founder of Acquifer based in Karlsruhe Germany at this year’s NIWeek, on the perspective of development of machine in the future. This interview tooked place in Austin, Texas at the beginning of August.

The development of HCS machines is possible with the collaboration of multi-disciplinary teams using customisable off-the-shelf technology. Ultimately, this powerful combination will drive disruptive innovation. As equipment becomes more cost effective, easier to use and more reliable, HCS capabilities will also become more readily available to a larger audience, accelerating the search for a cure to many diseases.

Curated from www.imveurope.com

Dr. Kim remarked, “Our research is significant in that we presented a candidate material for a new drug for without side effects.” He added, “We will try hard to develop a new drug for type 2 diabetes through a follow-up study using automated equipment for high-content screening recently built by the KBSI.”

by multiplexing assays on have many advantages to find more efficient new drugs for treatment. Progress in the IT part, on softwares, on the uses on big data and in the machine on speed and sensitivity allow to do multiplexing assays in HCS . This article shows us another example on this multiplexing assays on tumour and .

The high-throughput assay procedures use ready-made plates, open-source software and are compatible with standard plate readers, therefore offering high predictive power with substantial savings in time and money.

Curated from www.plosone.org

 

Before the discovery and development of molecular biology, screening assays to find new drugs was performed on animals. Since the last decade with , assays on whole organisms come back in primary screening.

In this article, the author have identified 20 potential stimulators of beta-cell replication on transgenic line.

This study establishes a proof of principle for a high-throughput small molecule-screen for beta-cell proliferation in vivo, and identified compounds that stimulate beta-cell proliferation and regeneration.

Curated from www.plosone.org

Join free Discovery Mini from GE Healthcare with scientists in the field of cellular analysis to discuss and get some new ideas around.

 



High Content Analysis assay design for better understanding of drug candidate mode of action. Achieving a high performance assay to investigate how molecules act in a functional cellular context can be challenging with respect to assay set-up and data analysis. Our experts will share their experiences from assay design, sample handling, data visualization, and interpretation.

Presenters: Cath Hather and Angela Williams

Curated from plus.google.com

Perkin Elmer is one of the leader in HCS equipment and furniture. To increase the quality of the results in cellular imagery, they have launched a new 384-well microplate : CellCarrier™ Ultra 384-well microplates.

We are really excited to test them!

Genetic Engineering & Biotechnology News (GEN) organise a free webinar about HCS ans HCA use in drug toxicity and genotoxicity testing.

High-content analysis (HCA) and high-content screening (HCS) enable imaging of large numbers of cellular samples for a variety of life science applications. Using automated high-resolution microscopy coupled with analytical software to visualize and quantify phenotypic responses in cells, HCS determines how compounds such as small molecule drugs, antibodies, or siRNA, affect cell morphology in a rapid, quantitative, high-throughput manner, providing meaningful functional readouts of cellular activity.

The broadcast date is Wednesday, June 11, 2014 at 10:00 am ET, 7:00 am PT, 4:00 pm CEST.

Follow this link to register : http://www.genengnews.com/webinars/high-content-screening-and-analysis-in-cell-based-assays-for-drug-toxicity-and-genotoxicity-tes/229/

Non-invasive cancer- diagnosis: a new application for HCS

HCS was first used in pharmaceutical industry to develop a new way to find new drugs. But this technology is extended since few years in other domains, as diagnosis!

source: http://www.int.laborundmore.de/news/694729/A-new-application-for-microscopy.html

%d bloggers like this: